SAN DIEGO, Aug. 31, 2023 /PRNewswire/ -- Neurelis, Inc. will present additional clinical findings from the completed long-term, open-label, repeat-dose safety study of VALTOCO for the treatment of ...
VALTOCO maintains orphan drug exclusivity for VALTOCO to treat episodes of frequent seizures SAN DIEGO, April 16, 2025 /PRNewswire/ -- Neurelis, Inc., today announced that the U.S. Food and Drug ...
SAN DIEGO, Oct. 4, 2023 /PRNewswire/ -- Neurelis, Inc., today announced additional findings from the post hoc analysis of the long-term phase 3 safety study of VALTOCO ® (diazepam nasal spray) in a ...
In this younger patient population, diazepam nasal spray was readily absorbed and demonstrated a consistent PK profile with that of older children and adults aged 6 to 59 years. The Food and Drug ...
Analysis of 12-month, Phase 3 study shows 2-fold increase in time between VALTOCO treated seizure clusters, or SEIzure interVAL (SEIVAL) SAN DIEGO, Oct. 12, 2022 /PRNewswire/ -- Neurelis, Inc., a ...
Sixth patent together with growing clinical evidence of the safety and effectiveness of VALTOCO reinforce clinical and commercial potential "We are pleased by our continued progress with the United ...
Valtoco (diazepam nasal spray) is a prescription medicine for quick and effective treatment of seizure clusters, also known as acute repetitive seizures, in people with epilepsy. Seizure clusters are ...
Largest, worldwide epilepsy community gathering will feature a physician presentation on VALTOCO ® (diazepam nasal spray) CIV for frequent seizure activity Little Angels Service Dogs' seizure alert ...
SAN DIEGO, Oct. 12, 2022 /PRNewswire/ -- Neurelis, Inc., a commercial-stage neuroscience company focused on the development and commercialization of therapeutics for the treatment of epilepsy and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results